Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22360655 | 0.84 | CES2 (0.40) | HSD17B10MEN1KMT2A | |
| SCHEMBL22360687 | 0.82 | CES2 (0.39) | HSD17B10MEN1KMT2A | |
| SCHEMBL16064919 | 0.75 | ALDH1A1 (0.37) | ALDH1A1LMNAHSD17B10MEN1KMT2A | |
| SCHEMBL19546267 | 0.70 | GPR84 (0.42) | ALDH1A1HSD17B10MEN1KMT2ATDP1 | |
| SCHEMBL9243513 | 0.69 | DGAT1 (0.41) | ALDH1A1LMNAHSD17B10MEN1KMT2A | |
| SCHEMBL13954111 | 0.67 | GAA (0.39) | ALDH1A1LMNAHSD17B10MEN1KMT2A | |
| SCHEMBL20489985 | 0.67 | ALDH1A1 (0.38) | ALDH1A1LMNAHSD17B10MEN1KMT2A | |
| SCHEMBL1685057 | 0.67 | TSHR (0.50) | ALDH1A1LMNAHSD17B10MEN1KMT2A | |
| SCHEMBL20026904 | 0.67 | ALDH1A1 (0.39) | ALDH1A1LMNAHSD17B10MEN1KMT2A | |
| SCHEMBL7763609 | 0.67 | LMNA (0.43) | ALDH1A1LMNAHSD17B10MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200261455-A1 | INHIBITORS OF MUTANT FAMILY TYROSINE-KINASES | SPECTRUM PHARMACEUTICALS, INC. | 2020-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200261455-A1 | INHIBITORS OF MUTANT FAMILY TYROSINE-KINASES | ERBB2, EGFR, ERBB3 | ALDH1A1 4557/4885LMNA 4355/4885HSD17B10 4328/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.